scholarly journals The Effect of Oligopin Supplementation on Hormonal and Metabolic Profiles in the Polycystic Ovary Syndrome: A Randomized Controlled Trial

2020 ◽  
Vol 11 ◽  
Author(s):  
Mostafa Qorbani ◽  
Milad Sanginabadi ◽  
Mohammad Reza Mohajeri-Tehrani ◽  
Sara Karimi ◽  
Hadis Gerami ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Metabolic Parameters ◽  
Sex Hormone Binding Globulin ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Specific Serum

BackgroundA double blind clinical trial was performed to evaluate whether the polycystic ovary syndrome (PCOS)-specific serum markers and metabolic parameters would change in the women with PCOS during the three-month administration of oligopin.MethodsIn this double-blind multicenter trial, we randomly assigned 80 PCOS women, based on a 1:1 ratio, to receive oligopin (n= 40) or maltodextrin as placebo (n = 40) for up to 3 months. As PCOS-specific outcomes, we investigated the changes in testosterone, sex hormone binding globulin (SHBG), free androgen index (FAI), dehydroepiandrosterone (DHEA), follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Secondary end points were metabolic (fasting glycaemia, hemoglobin A1c (HbA1c), lipids, insulin resistance (HOMA-IR)), anthropometrics parameters and blood pressure from the baseline to the end of treatment. We investigated serum transaminase, alkaline phosphatase (ALP), creatinine (Cr) and blood urea nitrogen (BUN) levels as hepatic and kidney outcomes, respectively.ResultsThe first participant was enrolled on April 18, 2018, and the last study visit took place on May 14, 2019. PCOS-specific serum parameters did not change during the three-month administration of oligopin (p > 0.05), except for a small increase in the FSH levels (p=0.03). Oligopin neither changed the metabolic profile nor the anthropometric parameters or blood pressure. ALP levels was significantly increased in placebo group, as compared with oligopin (p=0.01).ConclusionOligopin supplementation does not seem to be exerting a beneficial effect on both hormonal and metabolic parameters in the women with PCOS.Clinical Trial Registrationwww.irct.ir, identifier IRCT20140406017139N3.

scholarly journals Effect of Oligopin Supplementation on Polycystic Ovary Syndrome: A Randomized Controlled Trial

2020 ◽  
Author(s):  
Asieh Mansour ◽  
Milad Sanginabadi ◽  
Mohammad Reza Mohajeri-Tehrani ◽  
Sara Karimi ◽  
Hadis Gerami ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Metabolic Parameters ◽  
Sex Hormone Binding Globulin ◽  
Anthropometric Parameters ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Specific Serum

Abstract Background: A double blind clinical trial was performed to evaluate whether polycystic ovary syndrome (PCOS)-specific serum markers and metabolic parameters would change in women with PCOS during three months administration of oligopin. Methods: In this double-blind multicenter trial, we randomly assigned 80 PCOS women, in a 1:1 ratio, to receive oligopin (n= 40) or placebo (n = 40) for up to 3 months. As PCOS- specific outcomes, we investigated changes in testosterone, sex hormone binding globulin (SHBG), free androgen index (FAI), dehydroepiandrosterone (DHEA), follicle-stimulating hormone (FSH) and increase luteinizing hormone (LH). Secondary end points were metabolic (fasting glycaemia, hemoglobin A1c (HbA1c), lipids, insulin resistance (HOMA-IR)), anthropometrics parameters and blood pressure from baseline to end of treatment. We investigate serum transaminase, alkaline phosphatase (ALP), creatinine (Cr) and blood urea nitrogen (BUN) levels as hepatic and kidney outcomes, respectively. Results: PCOS-specific serum parameters did not change during three months administration of oligpin (p > 0.05) except for small increase in FSH levels (p=0.03). Oligopin neither changed the metabolic profile nor the anthropometric parameters or blood pressure. ALP levels significantly increased in placebo group compared with oligopin (p=0.01). Conclusion: Oligopin supplementation does not seem to be exerting a beneficial effect on both hormonal and metabolic parameters in women with PCOS.The study was registered at www.irct.ir with the identifier number of IRCT20140406017139N3.Registered 22 December 2018 - Retrospectively registered.

scholarly journals Effects of synbiotic supplementation on metabolic parameters and apelin in women with polycystic ovary syndrome: a randomised double-blind placebo-controlled trial

2018 ◽  
Vol 119 (4) ◽  
pp. 398-406 ◽  
Author(s):  
Elham Karimi ◽  
Ashraf Moini ◽  
Mehdi Yaseri ◽  
Nooshin Shirzad ◽  
Mahdi Sepidarkish ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Mean Difference ◽  
Metabolic Parameters ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Synbiotic Supplementation

AbstractPolycystic ovary syndrome (PCOS) is one of the most common causes of infertility in women of reproductive age. Insulin resistance is a main pathophysiologic feature in these patients. According to some studies, the intake of probiotic bacteria may improve glucose homoeostasis. The aim of this study was to investigate the effect of synbiotics on metabolic parameters and apelin in PCOS patients. This randomised double-blind placebo-controlled trial was conducted on eighty-eight PCOS women aged 19–37 years old. The participants were randomly assigned to two groups receiving (1) synbiotic supplement (n44), and (2) placebo (n44) for 12 weeks. Fasting blood samples were taken at baseline and after 12 weeks. The two groups showed no difference in fasting blood sugar (adjusted mean difference: 0·60; 95 % CI −3·80, 5·00,P=0·727), plasma glucose fasting 2-h (adjusted mean difference 2·09; 95 % CI −9·96, 14·15,P=0·134), HbA1c (adjusted mean difference 0·06; 95 % CI −0·09, 0·22,P=0·959), homoeostatic model assessment-insulin resistance (HOMA-IR) (adjusted mean difference: 0·02; 95 % CI −0·99, 1·03,P=0·837), quantitative insulin sensitivity check index (QUICKI) (adjusted mean difference: −0·02; 95 % CI −0·33, 0·29,P=0·940) and C-reactive protein (CRP) (adjusted mean difference: 0·24; 95 % CI −1·61, 2·08,P=0·141) by the end of the intervention. A significant difference was observed in the mean apelin 36 before and after the intervention between synbiotic and placebo groups (adjusted mean difference: −4·05; 95 % CI −7·15, −0·96,P=0·004). A 12-week synbiotic supplementation has no significant beneficial effects on HOMA-IR and CRP in PCOS patients, whereas the level of apelin 36 significantly decreased.

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

2008 ◽  
Vol 89 (5) ◽  
pp. 1221-1228 ◽  
Author(s):  
Åsa Lindholm ◽  
Marie Bixo ◽  
Inger Björn ◽  
Pål Wölner-Hanssen ◽  
Mats Eliasson ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Weight Reduction ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Decreased Sex Hormone-Binding Globulin Indicated Worse Biometric, Lipid, Liver, and Renal Function Parameters in Women with Polycystic Ovary Syndrome

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Xi Luo ◽  
Xin-Ming Yang ◽  
Wang-Yu Cai ◽  
Hui Chang ◽  
Hong-Li Ma ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Renal Function ◽  
Polycystic Ovary ◽  
Density Lipoprotein ◽  
Metabolic Parameters ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Ovary Syndrome ◽  
Renal Functions

Objective. To investigate the relationships between sex hormone-binding globulin (SHBG) and comprehensive metabolic parameters including biometric, glycemic, lipid, liver, and renal functions of women with polycystic ovary syndrome (PCOS). Study Design and Methods. A total of 1000 women diagnosed as PCOS by modified Rotterdam criteria were enrolled in a randomized controlled trial. SHBG and comprehensive metabolic parameters were measured at the baseline visit. Metabolic parameters included biometric parameters, glucose and lipid panels, and liver and renal function parameters. An independent t-test and linear regression were performed to investigate the associations between SHBG and metabolic parameters. Logistic regression was used to detect the relationship between SHBG and the presence of metabolic syndrome. Results. In comparative analyses, PCOS women with lower SHBG levels had higher body mass index, waist circumference, insulin, homeostatic model assessment-insulin resistance (HOMA-IR) index, systolic and diastolic blood pressure, triglycerides, apolipoprotein B (APOB), low-density lipoprotein (LDL), aspartate transferase (AST), alanine transferase (ALT), and blood urea nitrogen (BUN), but lower high-density lipoprotein (HDL) and apolipoprotein A1 (APOA1). In linear regression, SHBG was inversely associated with waist circumference, systolic blood pressure, triglyceride, LDL, APOB, ALT, AST, and BUN but positively associated with HDL and APOA1 after adjusting the BMI. In logistic regression, SHBG is a protective predictor for metabolic syndrome (odds ratio = 0.96; 95% confidence interval: 0.95–0.97). The area under the receiver-operator characteristic curve is 0.732 with a 95% confidence interval of 0.695–0.770. SHBG <26.75 mmol/L is the cutoff point with the best Youden index, which has a sensitivity of 0.656 and specificity of 0.698. Conclusions. Lower SHBG was associated with worsening biometric, lipid, liver, and renal functions but not glycemic parameters among women with PCOS. SHBG can be used as a tool to screen metabolic syndrome. This trial is registered with NCT01573858 and ChiCTR-TRC-12002081.

scholarly journals Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial

2011 ◽  
Vol 95 (5) ◽  
pp. 1849-1852 ◽  
Author(s):  
Nazia Raja-Khan ◽  
Allen R. Kunselman ◽  
Cynthia S. Hogeman ◽  
Christy M. Stetter ◽  
Laurence M. Demers ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Vascular Function ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Ovary Syndrome ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document